Header

UZH-Logo

Maintenance Infos

To B-(RAF) or not to be


Dummer, Reinhard; Goldinger, Simone M; Widmer, Daniel; Dreier, Jil; Levesque, Mitchell P (2014). To B-(RAF) or not to be. Journal of Investigative Dermatology, 134(5):1200-1201.

Abstract

The identification of targetable mutations has revolutionized the therapy of metastatic melanoma. In particular, BRAF and MEK inhibitors have a well-documented impact on overall survival in metastatic disease. However, therapeutic success is highly dependent on the correct identification of these mutations. We discuss the impact of molecular heterogeneity in this context.

Abstract

The identification of targetable mutations has revolutionized the therapy of metastatic melanoma. In particular, BRAF and MEK inhibitors have a well-documented impact on overall survival in metastatic disease. However, therapeutic success is highly dependent on the correct identification of these mutations. We discuss the impact of molecular heterogeneity in this context.

Statistics

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:May 2014
Deposited On:26 Feb 2015 11:43
Last Modified:08 Dec 2017 12:01
Publisher:Elsevier
ISSN:0022-202X
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1038/jid.2014.62
PubMed ID:24732335

Download

Full text not available from this repository.
View at publisher